← Therapeutics
Details checkedClinical trial listing onlyCheckedregistry
Antioxidant prevention study for noise-induced hearing loss and tinnitus
Also known as: Antioxidantia, N-acetylcysteine plus magnesium
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Not applicable
Status
Unknown
Target Gene
—
Route / Mode
Oral
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
Belgium
Population
adult, noise-induced, tinnitus
Trial IDs
1
Mechanism
Double-blind placebo-controlled crossover study of N-acetylcysteine plus magnesium taken before high-level leisure noise exposure to prevent noise-induced hearing loss and tinnitus.
Indications
Notes
Registry-verified academic prevention study. The registry status is unknown and no current commercial program is verified.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, company, allCompanies, isIndustrySponsored, programType, modality, mechanism, indications...
IDs: NCT01727492
Key Events
Clinical Trials (1)
Data Checks
institution-led-studyregistry-only-evidencecurrent-status-unknown-in-registrynot-confirmed-current-product
Related Programs
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
AC102 by AudioCure Pharma
Company: AudioCure Pharma · Small Molecule · Phase 2
SPI-1005 by Sound Pharmaceuticals
Company: Sound Pharmaceuticals · Small Molecule · Phase 3
ACOU085 by Acousia Therapeutics
Company: Acousia Therapeutics GmbH · Small Molecule · Phase 2
CIL001 (Paliroden) by Cilcare
Company: Cilcare SAS · Small Molecule · Phase 1/2